Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics, Inc. (APGE)
:APGE
RESEARCH TOOLSreports
APGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.46 - $72.29
Previous CloseN/A
Volume109.80K
Average Volume (3M)568.88K
Market Cap
$1.99B
Enterprise Value$2.82B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Mar 11, 2025EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding45,026,554
10 Day Avg. Volume601,374
30 Day Avg. Volume568,884
Standard Deviation0.27
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-16.35
Forecast
1Y Price Target
$94.00Price Target Upside176.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Apogee Therapeutics News
PremiumCompany Announcements
Apogee Therapeutics Advances APG777 in Key Phase 2 Trial
PremiumCompany Announcements
Apogee Therapeutics Advances Clinical Trials for APG333
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFull enrollment was achieved in the Ph2a study for APG777 in atopic dermatitis, indicating strong progress in clinical trials.
Efficacy And DosingAPG777 monotherapy should deliver an improved dosing interval with significantly fewer induction and maintenance doses, and the potential to demonstrate improved efficacy from the already strong SOC.
Market OpportunityApogee's programs have a $100B+ TAM, which could lead to tens of billions of value created.
Bears Say
CompetitionLebrikizumab received FDA approval with on-label dosing regimens corresponding to a minimum annualized WAC of $66.5k in year 1 and $45.5k thereafter, supporting a strong early launch that could read through positively to APG777.
Financial OutlookPatients who reported adverse effects of interest with Dupixent did not have the same experience on lebrikizumab, and the majority of patients discontinuing Dupixent due to adverse effects remained on lebrikizumab therapy.
Market ChallengesThe segment corresponds to a large opportunity, as >50% of Dupixent-treated patients have suboptimal responses and likely stay on Dupixent longer than otherwise appropriate, given the lack of post-Dupixent, non-JAK Tx options.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $32.46 and its highest was $72.29 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Apogee Therapeutics, Inc.’s market cap is $1.99B.
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2025 which is in 17 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$0.879 by $0.019.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -1.08.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 45,026,554 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$0.86 in its last earnings report, beating expectations of -$0.879. Following the earnings report the stock price went down -5.144%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Currently, no hedge funds are holding shares in APGE
---
Apogee Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.00 (176.88% Upside)
$94.00 (176.88% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $990.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.14%
12-Months-Change
Fundamentals
Return on Equity
-25.65%
Trailing 12-Months
Asset Growth
82.05%
Trailing 12-Months
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
---
APGE Stock 12 Month Forecast
Average Price Target
$94.00
▲(176.88% Upside)
Technical Analysis
Best Analysts Covering APGE
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+14.12%
reiterated a buy rating 14 days ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +14.12% per trade.
---